The Effects of Nicorandil and Nifekalant, Which Were Injected into the Pericardial Space, for Transmural Dispersion of Repolarization in the Pig  by Ito, Hiroyuki et al.
The Eﬀects of Nicorandil and Nifekalant, Which Were
Injected into the Pericardial Space, for Transmural
Dispersion of Repolarization in the Pig
Hiroyuki Ito MD, Taku Asano MD, Youichi Kobayashi MD, Tatsuya Onuki MD,
Fumito Miyoshi MD, Taka-aki Matsuyama MD, Yoshino Minoura MD,
Norikazu Watanabe MD, Mitsuharu Kawamura MD, Kaoru Tanno MD,
Takashi Katagiri MD
Third Department of Internal Medicine, Showa University, Tokyo, Japan
Introduction: Some studies have reported that transmural dispersion of repolarization
(TDR) is involved in the onset of ventricular arrhythmia. We investigated the eﬀects of
nicorandil (NIC) and nifekalant (NIF) injected into the pericardial space, on TDR and T
waves in the pig. Methods and Results: We injected NIC 4 or 8mg and NIF 50 or 100mg at
intervals into the pericardial space for eleven pigs. The eﬀects of these drugs were
investigated on the eﬀective refractory period (ERP) between the endocardial and epicardial
myocardial cells, as well as on QT time, QT peak-end (QTcpe) as an index of TDR, and T
waveforms, respectively. QTcpe increased from 91 21 to 116 19msec, 2.8min after
injection of NIC (p < 0.01), although corrected QT (QTc) interval did not changed. But 5.5
min after injection, QTc decreased while QTcpe recovered. T wave amplitude signiﬁcantly
increased, and epicardium ERP decreased. When NIF was injected, TDR decreased from 55
10msec to 44 8msec (p < 0.01) although QTc did not change. In a later phase, QTc
increased (p < 0.01) and QTcpe recovered. T wave amplitude rapidly decreased and became
negative. Conclusion: Injected into the pericardial space, NIC and NIF brought about certain
changes in ERP, QT and T waveform. Furthermore, NIC increased TDR while NIF decreased
TDR.
(J Arrhythmia 2007; 23: 46–57)
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Introduction
In recent years, some studies have reported that
dispersion of repolarization time from epicardial
cells to endocardial cells (transmural dispersion of
repolarization; TDR) is involved in ECG changes
associated with Brugada syndrome and in the onset
of ventricular arrhythmia.1–3) Short QT syndrome
(SQTS) is a novel genic disorder that occurs in
individuals with a structurally intact heart and
Address for correspondence: Hiroyuki Ito MD, Third Department of Internal Medicine, Showa University, 1-5-8 Hatanodai,
Shinagawa-ku, Tokyo 142-8600, Japan. Tel: 03-3784-8539 E-mail: hiroic2004@yahoo.co.jp
Received 9, January, 2007: accepted in ﬁnal form 9, February, 2007.
46
J Arrhythmia Vol 23 No 1 2007
Original Article
an increased susceptibility to ventricular arrhythmia
and sudden death.17) Priori et al. reported SQT3,
which has a unique ECG phenotype characterized
by asymmetrical T waves, and a defect in the gene
coding for the inwardly rectifying Kir2.1 (IK1)
channel.4,5)
Nicorandil (NIC) has been shown to open IK-ATP
channels and shorten QT and eﬀective refractory
period (ERP).6–8) Nifekalant (NIF) blocks IKr chan-
nels to extend action potential duration (APD) in
a frequency-dependent manner, and this increases
QT time and ERP. Recently, it has been used as a
ﬁrst-line drug in cardiopulmonary resuscitation.9,10)
When administered intravenously, NIF increases
TDR, induces phase 2 re-entry, and causes Torsade
de Pointes,6,7) possibly because of increasing ERP in
the endocardial myocardium. So, if NIF is adminis-
trated into the pericardial space, theoretically TDR
may become shortened. However, to the best of our
knowledge, there have been no studies into admin-
istering these drugs into the pericardial space.11)
The purpose of this study was to investigate the
eﬀects of NIC and NIF, which were injected into
the pericardial space of pigs, on the ERP of the
endocardial and epicardial myocardial cells, as well
as on QT time, TDR and waveforms, as measured
by surface ECG. Furthermore, prevention of phase 2
re-entry by pericardial injection and reproducibility
of Brugada-like and short QT syndrome-like ECG
waveforms were investigated.
Subjects and Methods
Subjects were eleven female pigs aged 3–4
months and weighing 31 2 kg. The following three
drugs were prepared: an injection containing 50mg
or 100mg of NIF, an injection containing 4mg or
8mg of NIC, and physiological saline at 37C as
control. Each drug preparation was dissolved in
physiological saline at 37C (total 5ml) immediately
before injection.
Pigs were placed in the supine position and
arterial oxygen saturation was monitored. Anesthesia
was induced with 5mg/kg of xylazine and 5mg/kg
of ketamine intravenously, and maintained with
inhaled 1.1%	2.7% isoﬂurane. Pigs were intubated
and ventilated with N2O and O2 (1:1). The Seldinger
method was employed to puncture the right internal
carotid vein and both femoral veins and arteries, and
a 7 or 8 French sheath was inserted into each artery
and vein. Through the sheath placed in the right
internal carotid vein and the left and right femoral
veins, multiple electrode catheters (Boston Scientif-
ic-EP Technologies) were placed: an 8-electrode
catheter in the high right atrium, an 8-electrode
catheter in the right cardiac apex, and a 10-electrode
catheter in the coronary sinus. In addition, from the
left margin of the sternum in the fourth intercostal
space, pericardiocentesis was performed using an
epidural needle (17G). Small amounts of contrast
media were injected through the needle as it was
advanced into the pericardial space under ﬂuoro-
scopic guidance. When the pericardial space was
thought to be reached, a small bolus of contrast
media was injected, and this was conﬁrmed by
diﬀusion of contrast media throughout the pericar-
dial space. A guide wire was then passed through
the needle, over which the 8F sheath was advanced.
Through the sheath placed in the epicardial space,
a 7 Fr electrode catheter was inserted and placed
on the anterior wall side of the left ventricular
epicardium under ﬂuoroscopic guidance in order to
perform the electrophysiological study (Figure 1).
1. Methods for drug injection
Drug injection followed the schedule shown in
Figure 1. As a control, 10ml of physiological saline
(37C) was injected into the pericardial space over
a 30-s period, and EPS was performed starting at
1min after the injection. The pig was monitored
for 5min after the injection, and the drug solution
was eliminated. Next, after a break of about 10min,
either 4 or 8mg of NIC was dissolved in 37C
physiological saline to bring the volume to 10ml,
and this was then injected into the epicardial space
over a 30-s period. At 1min after the end of in-
jection, EPS was started. The pig was monitored
for 10min after the end of injection, and the drug
solution was eliminated. Next, 10ml of 37C physio-
logical saline was injected to wash out the epicardial
cavity and was then drained. Because the half-life of
NIC is short, drug eﬀects disappeared within 10min
of draining the drug solution. Either 50 or 100mg of
NIF was then dissolved in 37C physiological saline
to bring the volume to 10ml, and this was then
injected into the epicardial space over a 30-s period.
ERP measurement was initiated at 1min after the
injection. ERP was measured from both epicardial
and endocardial sides at the same tame. The pig
was monitored for 30min after the end of injection,
and the drug solution was then drained. During this
period, surface ECG was continuously monitored.
The same procedures were performed on each of the
eleven pigs.
2. Observation items and test methods
1) Electrophysiological test
From each electrode catheter placed in the left
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ventricular apical endocardium and epicardium,
continuous stimulation with a basic cycle length
(BCL) of either 400 or 500ms was applied, and the
minimal output with which the left ventricle re-
sponded was measured as the threshold value. The
intensity of ventricular stimulation was twice the
threshold value, and further experiments were con-
ducted.
After delivering stimulation seven times at 400 or
500ms BCL by the early stimulation method, the
shortest interval for QRS waves in relation to single
early simulation with a shortened interval was
measured as ERP. Measurement was started 1min
after the injection and required about 5min to
complete. In three pigs, ERP was also measured at
8min and 18–20min after the injection.
2) ECG
Using Cardio Lab (GE Medical), surface 12-lead
and intracardiac ECG was digitally recorded con-
tinuously. Paper speed was set at 50mm/s with a
gain of 20mm/mV. RR interval (msec), QT time
(msec) and T wave height (mV) in V1 lead were
measured on the Cardio Lab screen every 30 sec
from immediately before drug injection to 5min
after injection, every 1min from 5 to 10min after
injection, every 2min from 10 to 20min after in-
jection, and every 3min from 20 to 30min after
injection. As shown in Figure 2, QT peak (QTp) was
deﬁned as the distance from the starting point of the
QRS complex to the peak of the T wave, serving as
an indicator for APD of myocardium of epicardial
side. QTend (QTe) was deﬁned as the distance from
the starting point of the QRS complex to the end
point of the T wave, and was measured by the
tangential method, serving as an indicator for the
APD of M cells distributed in the middle myocardial
layer. QTpeak-end (QTpe) was deﬁned as the
distance from the peak of the T wave to the end
point of the T wave, serving as an indicator for
TDR.1)
Perform pericardiocentesis; place catheters
1. Physiological saline (PS, 37°C, 10ml) injection
EPS (1min. after injection)
ECG monitoring for 5min.
2. Nicorandil 4mg or 8mg injection
after dissolution in PS(37°C, 5ml)
flush out with PS 5ml
ECG monitoring for 10min.
3. Nifekalant 50mg or 100mg injection
after dissolution in PS(37°C, 5ml)
EPS(1min. after injection)flush out with PS 5ml
ECG monitoring for 30min.
Washout: elimination
Pericardiocentesis
Catheter locations
guide wire
contrast media
Coronary sinus
LVepi
LVendoHRA
puncture site
Washout: elimination PS(37°C, 20ml) 
injection elimination 10min. brake 
eliminationinjection 10min. brake
PS(37°C, 20ml) 
EPS(1min. after injection)
Protocol of drug injection 
Figure 1 Drug injection protocol and catheter location.
After pericardiocentesis, catheters were located at the position of the photo.
EPS: electrophysiological study, ECG: electrocardiogram, LV (endo, epi): left ventricular (endocardium, epicardium), HRA: high right
atrium
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After correcting using Budget’s formula (QTc =
QT/RR1=2), each parameter (QTcp, QTce and
QTcpe) was expressed as mean  standard devia-
tion (SD) and was then plotted. The heart rate was
close to 100 bpm while calculating. Comparison was
made among four time points: (1) before injection,
(2) maximum change in QTcpe after injection, (3)
maximum change in QTce, and (4) end of observa-
tion.
3) Plasma concentration
Blood samples were collected at 1, 5, 10, 15, 20
and 30min after injecting NIF, and plasma concen-
tration was measured by HPLC (Mitsubishi BCL).
4) Ethics
The current study was performed according to the
Guidelines for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health. The study protocol was reviewed by the
Committee of the Ethics on Animal Experiments of
Showa University.
3. Analysis methods
Chronological changes in ERP and ECG param-
eters (repeated comparison to before drug injection)
were analyzed, and stratiﬁed comparison (low-dose
group, high-dose group, epicardium group and
endocardium group) was carried out using 2-sample
t-test or paired t-test. These analyses were performed
with the Stat View 5J program (SAS Institute, Cary,
NC). Signiﬁcant diﬀerences were deﬁned as p <
0.05, while p < 0.1 was considered to indicate a
trend.
Results
1. QT time, QTc peak-end (QTcpe) in V1
When physiological saline was injected, no clear
changes were seen in QTce, QTcp or QTcpe before
and after injection (p = NS) (Figure 3a).
After 8mg of NIC was injected, no signiﬁcant
changes were seen in either QTcp or QTce in the
early phase (2:8 0:7min after injection), but
QTcpe signiﬁcantly increased from 91 21ms to
116 19ms (p < 0.01). In the later phase (5:5
3:3min after injection), QTce changed from 486
34ms (before injection) to 459 23ms (p < 0.1),
while QTcpe recovered. 10min after injection, QTce
also recovered to 474 46ms (p < 0.05). When
4mg of NIC was injected, the results were nearly the
same as for an 8mg injection (Figure 3b).
After 100mg of NIF was injected, no signiﬁcant
changes were seen in either QTcp or QTce in the
early phase (5:1 2:3min), but QTcpe signiﬁcantly
decreased from 56 10ms to 44 8ms (p < 0.01).
Then, in the later phase (9:7 3:0min after injec-
tion), both QTce and QTcp signiﬁcantly changed
from 457 44ms and 401 42ms (before injec-
tion) to 540 49ms and 485 40ms, respectively
(p < 0.01), but neither of the values recovered, even
at 30min after injection, while QTcpe simultane-
ously recovered to the control levels. When 50mg of
NIF was injected, the results were nearly the same as
for a 100mg injection (Figure 3c).
2. Amplitude and morphology of T wave in V1
When physiological saline was injected, T wave
amplitude showed no clear changes (p = NS)
(Figure 4a). When 8mg of NIC was injected, T wave
amplitude increased from 0:543 0:179mV to
0:897 0:335mV (3.5min after injection) (p <
0.05), which was higher than 4mg-injection in a
dose-dependent manner (Figures 4b and 5a). In addi-
tion, these changes gradually recovered to pre-drug
levels as measured by the changes in QTcpe. On the
other hand, when 50mg of NIF was injected, T wave
amplitude decreased from 0:433 0:301mV before
injection to 0:107 0:192mV at 10min after in-
jection (p < 0.01). When 100mg of NIF was in-
jected, T wave amplitude rapidly decreased from
0:25 0:10mV before injection to 0:01 0:11
mV at 3.5min after injection (p < 0.01). T wave
amplitude tended to have a negative value at 4.5min
QTp
QTe
QTpe
R
P
Q S
T
U
Figure 2 QRS measurement methods in V1.
QT peak (QTp) was deﬁned as the distance from the starting point
of the QRS complex to the peak of the T wave. QTend (QTe) was
deﬁned as the distance from the starting point of the QRS complex
to the end point of the T wave, and was measured by the tangential
method, serving as an indicator for the APD of M cells distributed
in the middle myocardial layer. QTpeak-end (QTpe) was deﬁned
as the distance from the peak of the T wave to the end point of the
T wave, serving as an indicator for TDR.
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Figure 3 QTc (physiological saline, NIC and NIF).
QTcp: Corrected QT peak, QTce: Corrected QT end, and QTcpe: Corrected QT peak-end. No clear changes were seen in QTce or
QTcpe before and after injection of physiological saline (p = NS). At 4:1 2:5min after injection, NIC 4mg signiﬁcantly decreased
QTce and QTcp. At 9:7 3:0 after NIF 100mg injection, both QTcp and QTce increased signiﬁcantly and remained high at 30min after
injection.
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Figure 4 Time course of T wave
amplitude in V1 lead (physiological
saline and NIC, NIF).
Physiological saline did not cause any
signiﬁcant change in T wave amplitude.
Starting at 30 s after NIC injection, T
wave amplitude increased rapidly (p <
0.05) for about 3min, after which it
gradually recovered. At twice the dose,
T wave amplitude increased even fur-
ther. After NIF injection, T wave am-
plitude decreased gradually, and at 100
mg, T wave height had a negative value
in some cases.
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Before
(NS10ml) 1min. 5min. 10min. 15min.
0.5mV/1cm,
50mm/sec
I
II
III
V1
V2
V3
a.
Before
(NS 10ml) 1min. 5min. 10min. 15min.
0.5mV/1cm,
50mm/sec
20min. 30min.
I
II
III
V1
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V3
b.
Figure 5 Time course of T wave morphology (NIC 8mg).
a: When 4mg of NIC was injected, T wave amplitude signiﬁcantly increased (2min after injection) (p < 0.01), while 8mg of NIC
increased (3.5min after injection) (p < 0.05) in a dose-dependent manner.
b: T wave height amplitude rapidly decreased after injection. T wave amplitude tended to have a negative value at 4.5min after injection.
J Arrhythmia Vol 23 No 1 2007
52
after injection, decreasing from 0:25 0:10mV
before injection to 0:051 0:10mV (Figures 4c
and 5b).
3. ERP
After physiological saline was injected, ERP
showed no clear changes (p = NS) (Figure 6). When
8mg of NIC was injected, ERP on the epicardial side
signiﬁcantly decreased from 292 46ms to 268
15ms (p < 0.01), although 4mg of NIC made no
signiﬁcant diﬀerence. However, ERP on the endo-
cardial side showed no clear changes (p = NS).
After 50mg of NIF was injected, ERP on the epi-
cardial side increased signiﬁcantly from 285 34ms
to 312 31ms (p < 0.01). However, ERP on the
endocardial side showed no clear changes, increas-
ing slightly from 292 24ms to 308 28ms (p =
NS).
When 100mg of NIF was injected, ERP on both
the endocardial and epicardial sides increased sig-
niﬁcantly from 270 35ms to 322 28ms and
from 275 34ms to 321 30ms, respectively (p <
0.01).
Figure 7 shows chronological changes in ERP.
When 8mg of NIC was injected, ERP on the
epicardial side decreased from 292 46ms before
injection to 268 15ms at 1min after injection
(p < 0.01) and recovered to 290 24ms at 8min
after injection. With some delay when compared
to the epicardial side, ERP on the endocardial side
decreased slightly from 307 25 at 1min after in-
jection to 293 31ms at 8min after injection (p <
0.1), and then recovered to 303 25ms. When NIF
was injected, ERP on the epicardial side before in-
jection was 285 34ms, increased to 312 31ms
at 1min after injection (p < 0.01), and remained
high for 20min. On the endocardial side, ERP before
injection was 293 25ms, and this increased to
333 33ms at 8min after injection, which was
1min later than the increase on the epicardial side
(p < 0.01).
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Figure 6 ERP.
ERP (physiological saline); Following physiological saline injection, no signiﬁcant diﬀerences were seen in epicardial and endocardial
ERP.
ERP (NIC and NIF); Following 8mg NIC injection, ERP decreased only on the epicardial side. Following 50mg NIF injection, ERP
signiﬁcantly increased only on the epicardial side. Therefore it was thought that at 1–5min after injection, the pharmacological eﬀects of
NIC and NIF were only apparent on the epicardial side. But with a dose of 100mg, inﬁltration to the endocardial side was faster, thus
negating the diﬀerence between the epicardial and endocardial sides.
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5. Plasma concentration
Figure 8 shows shifts in the plasma concentration
of NIF following intravenous administration into
humans12) and pericardial injection to pigs. When
50mg of NIF was injected into the pericardial space
of a pig, the plasma concentration of NIF at 5min
after injection was 225 107 ng/ml, which was
comparable to that at 5min after intravenous in-
jection (0.2mg/kg) to a human. When 100mg of
NIF was injected, the plasma concentration of NIF
at 5min after injection was 419 273 ng/ml, which
was comparable to that at 5min after intravenous
injection (0.3mg/kg) to a human. At these plasma
concentrations, there was no signiﬁcant arrhythmo-
genecity.
Discussion
The main ﬁndings of this study are as follows.
When NIC or NIF was injected into the pericardial
space, QTcpe (TDR indicator) increased or decreas-
ed in the early phase, and recovered in the later
phase. This shows that both drugs were eﬀective
only on the epicardial side in the early phase, which
is from 1min to 4min after injection for NIC and
from 1min to 8min after injection for NIF.
When NIC was injected into the epicardium, the
shape of T waves became acute in all cases, and T
wave amplitude exhibited dose dependency. On the
other hand, when NIF was injected, the shape of T
waves edged down in a dose-dependent manner.
1. QT time and TDR
In a study using sections of arterially perfused left
ventricular myocardium, Shimizu et al. reported that
QTpeak, as assessed by surface ECG, represents the
APD of epicardial myocardium, while QTend rep-
resents the APD of M cells (mid-myocardial cells in
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Figure 7 Time course of ERP.
With NIC, ERP decreased on the epicardial side at 1min after injection and recovered at 8min after injection. With
some delay, a mild decrease was seen on the endocardial side at 8min after injection, and ERP recovered at 18min after
injection. With NIF, ERP increased signiﬁcantly on the epicardial side at 1min after injection, and it remained high for
20min after injection. On the endocardial side, a clear increase was seen at 8min after injection.
J Arrhythmia Vol 23 No 1 2007
54
the middle myocardial layer).1) They also proposed
QTcpe (peak-end) as a TDR indicator, which is
involved in the ECG changes associated with
Brugada syndrome and in the onset of ventricular
arrhythmia.1) In the present study, NIC increased
QTcpe without changing QTce in a early phase, thus
suggesting that NIC only shortened the APD of the
epicardial side and quickly increased TDR. Further-
more, in a later phase, QTce also shortened, while
TDR tended to recover.
On the other hand, NIF shortened QTcpe without
changing QTce in an early phase, thus suggesting
that NIF only increased epicardial APD and decreas-
ed TDR. Furthermore, in a later phase, QTce also
increased and TDR tended to recover. These results
show that injection of NIC or NIF into the peri-
cardial space expresses their pharmacological eﬀects
over time from the epicardial myocardium to the
endocardial myocardium, and the QT-decreasing or
increasing eﬀects of the present study do not con-
tradict the results of those injected intravenously.
A clinical implication which may be inferred is that
an NIF injection into the epicardial side may be
useful for preventing phase 2 reentry. In the future,
administration of these drugs to the epicardial side
during open-heart surgery or in epicardial ablation
for intractable arrhythmia13) is also expected.
2. Amplitude and morphology of T wave
Many cases of idiopathic ventricular ﬁbrillation
(VF) in younger individuals with structurally normal
hearts have been documented.14) Some of what was
thought to be idiopathic is now better deﬁned as
speciﬁc clinical entities, such as long QT syndrome,
Brugada syndrome, catecholaminergic ventricular
tachycardia (VT) and short QT syndrome (SQTS).15)
SQTS is characterized by a high incidence of syn-
cope, sudden cardiac death and supraventricular
arrhythmias, short refractory period and inducibility
of VF during programmed electrical stimulation.16)
Among the subtypes of SQTS, SQT3 (KCNSJ2) is
particularly characterized by an asymmetrically
shaped T wave with a rapidly descending limb, and
a peculiarly tall and narrow T-wave shape.17) In this
study, when NIC was injected into the epicardium,
the shape of T waves assumed unusually tall and
narrow shapes in all cases, and T wave amplitude
exhibited dose dependency. As a result, short QT
syndrome-3 like waveforms17) were seen. Further-
more the ST-segment was also elevated after in-
jection. When NIF was injected, the shape of T
waves edged down in a dose-dependent manner.
Brugada syndrome is characterized by ST-segment
elevation in the right precordial leads (V1–3) and an
episode of VF in the absence of structural heart
disease.18) In an experimental Brugada syndrome
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Figure 8 Plasma concentration of
NIF following intravenous adminis-
tration (humans) or pericardial injec-
tion (pigs).
Even when large doses of NIF are
injected into the epicardium, large
amounts of the drug are not transferred
to the circulating blood. Furthermore, at
these plasma concentrations there was
no signiﬁcant arrhythmogenecity.
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model using arterially perfused right ventricular
myocardial sections, pinacidil, a Kþ channel opener,
enhanced ST-segment elevation.19) It is also reported
that late r0 waves and ST elevation become prom-
inent just before VF episode in Brugada syndrome.20)
However, the mechanism responsible for ST eleva-
tion in Brugada syndrome remains unclear. Follow-
ing epicardial injection of NIC, an IK-ATP chan-
nel opener, outward Kþ current in the epicardial
myocardium increased, thus making ST-segment
elevation more notable, in addition to the T wave
changes.
3. ERP
When NIC was injected into the pericardial space,
ERP decreased. This does not contradict the ERP-
decreasing action of intravenous NIC. When NIF
was injected into the pericardial space, ERP increas-
ed. This does not contradict the ERP-increasing
action of intravenous NIF either. ERP was also
measured in time intervals after NIC and NIF
injection into the pericardial space, and pharmaceut-
ical eﬀects were seen earlier in the epicardium
than in the endocardium. The results show that the
pharmacological eﬀects of NIC and NIF are only
apparent on the epicardial side shortly after injection.
Thus a drug injection into the pericardial space
seems more eﬀective, especially on the epicardial
side, than an intravenous injection.
After 8mg of NIC was injected, ERP signiﬁcantly
decreased only on the epicardial side, although 4
mg of NIC resulted in no signiﬁcant changes. On
the other hand, at a dose of 50mg, NIF markedly
increased ERP on the epicardial side alone, but at
a dose of 100mg, NIF increased ERP both on
the epicardial and endocardial side. Above results
suggested that 4mg of NIC was too small an amount
to change the ERP of both the epicardial and
endocardial side, and that 100mg of NIF was too
large an amount making the inﬁltration from the
epicardial side into the endocardial side too fast, thus
no diﬀerence was seen between the epicardial and
endocardial sides (Figure 6). It was thought that
about 8mg of NIC and about 50mg (1.6mg/kg) of
NIF was the optimal dose.
4. Plasma concentration
At 5min after injecting 100mg of NIF into the
pericardial space of pigs or intravenously adminis-
tering 0.3mg/kg NIF to humans, both plasma
concentrations of NIF were about 400 ng/ml. The
results show that NIF injected into the pericardial
space moved quickly from the epicardial side to the
endocardial side, and aﬀected electrophysiological
activity in the same way as did intravenous injection.
In addition, it also showed that even when large
doses of NIF are injected into the epicardium, large
amounts of the drug are not necessarily transferred to
the circulating blood.
Conclusions
When injected into the pericardial space, NIC
and NIF brought about speciﬁc changes in ERP, QT
and T waveform. Furthermore, NIC increased TDR,
while NIF decreased TDR.
Limitations
Although the result of this study suggested the
usefulness of epicardial administration of NIC and
NIF for ventricular arrhythmia, certain study limi-
tations must be noted. First, the number of subjects
was limited. Second, it has not been conﬁrmed that
the clinical eﬀects of NIC and NIF to pigs can be
applied to human beings. We are planning to
continue to evaluate the signiﬁcance of this ﬁnding
by increasing the number of subjects.
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